GSK Investigational Site

Cherry Hill, New Jersey 8034

0 studies enrolling now · 18 studies all time

What they study most

Asthma, Diabetes Mellitus, Type 2, Epilepsy, Epilepsy, Tonic-Clonic, Hypertension, Migraine Disorders, Migraine, Acute, Neoplasms, Breast, Pulmonary Disease, Chronic Obstructive, Restless Legs Syndrome, Restless Legs Syndrome (RLS), Thrombocytopaenia

Studies at this site

• Converting From Ropinirole Immediate Release (IR) To Ropinirole Controlled-Release for RLS (Restless Legs Syndrome) — Completed
• A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• A 24-week Evaluation of GSK573719/Vilanterol (125/25mcg) and Components in COPD — Completed
• Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD) — Completed
• Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide — Completed
• Treatment Of Primary Generalized Tonic-Clonic Seizures With An Investigational New Drug — Completed
• HZA113091 Efficacy and Safety of Fluticasone Furoate/Vilanterol (GW642444) in Adults and Adolescents — Completed
• Pediatric Epilepsy Study in Subjects 1-24 Months — Completed
• The COREG And Lisinopril Combination Therapy In Hypertensive Subjects (COSMOS) Trial — Completed
• A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma — Completed
• Long-Term Safety Of Ropinirole XR In Patients With Restless Legs Syndrome — Completed
• Study In Subjects With COPD (Chronic Obstructive Pulmonary Disease) — Completed
• ADVAIR® DISKUS® Inhaler (Fluticasone Propionate/Salmeterol) Versus SEREVENT® DISKUS® Inhaler (Salmeterol) For The Treatment Of Chronic Obstructive Pulmonary Disease Exacerbations. ADVAIR® DISKUS® Inhaler and SEREVENT® DISKUS® Inhaler Are Trademarks of the GSK Group of Companies. — Completed
• Pediatric Epilepsy Trial in Subjects 1-24 Months — Completed
• GSK BHR Study (Sont) — Completed
• Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag — Completed
• Tykerb Evaluation After Chemotherapy (TEACH): Lapatinib Versus Placebo In Women With Early-Stage Breast Cancer — Completed
• TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults — Completed